<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700332</url>
  </required_header>
  <id_info>
    <org_study_id>184-20-CA</org_study_id>
    <nct_id>NCT04700332</nct_id>
  </id_info>
  <brief_title>PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer</brief_title>
  <official_title>2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (PyL) in Patients With High Risk and Biochemically Recurrent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoag Memorial Hospital Presbyterian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoag Memorial Hospital Presbyterian</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard of care imaging of prostate cancer metastases recommended by the National&#xD;
      Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be&#xD;
      suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen&#xD;
      (PSMA) expressed on prostate cancer cells. PyL PET/CT may provide improved evaluation of&#xD;
      clinically significant metastases in patients with prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a phase II clinical trial to assess the clinical value of PyL for detection of&#xD;
      disease in pateints with:&#xD;
&#xD;
        1. High risk prostate cancer and planned prostatectomy or radiation therapy (arm 1) and&#xD;
&#xD;
        2. Biochemically recurrent prostate cancer (arm 2) but without evidence of disease of&#xD;
           standard of care imaging (CT of the chest/abdomen/pelvis and bone scan).&#xD;
&#xD;
      In both cohorts, PyL PET/CT will be obtained and evaluated by a nuclear radiologist trained&#xD;
      in novel PET radiotracers, including PyL. Lesions suspicious for disease of PyL that were&#xD;
      unsuspected on standard of care imaging will be selected for biopsy for pathologic&#xD;
      confirmation if feasible . Pathology will be used as the reference standard for confirming&#xD;
      malignancy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of unsuspected metastases in high risk prostate cancer</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Determine the rate of detection of unsuspected metastases in patients with high risk prostate cancer and planned prostatectomy or radiation therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Detection of unsuspected metastases in biochemically recurrent prostate cancer</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Determine the rate of detection of unsuspected metastases in patients with biochemically recurrent prostate cancer, yet no evidence of disease on CT/bone scan.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>High risk prostate cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCFPyL PET/CT will be compared to CT/bone scan for detection of unsuspected metastases in patients with high risk prostate cancer and planned prostatectomy or or radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biochemically recurrent prostate cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCFPyL PET/CT will be utilized for detection of unsuspected metastases in patients with biochemically recurrent prostate cancer, but with no evidence of disease on CT/bone scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCFPyL PET/CT</intervention_name>
    <description>Prostate Membrane Specific Antigen-specific imaging</description>
    <arm_group_label>Biochemically recurrent prostate cancer</arm_group_label>
    <arm_group_label>High risk prostate cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male ≥ 18 years of age.&#xD;
&#xD;
          2. Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          3. Patients meet one of the follow criteria:&#xD;
&#xD;
        Cohort 1: High risk prostate cancer (PSA &gt;10, Gleason 8-10, or clinical stage &gt;T2c) and&#xD;
        planned prostatectomy or radiation therapy or Cohort 2: Biochemical prostate cancer relapse&#xD;
        (Prostate Specific Antigen (PSA) &gt; 0.2 ng/ml in patients following prostatectomy or ≥ 2&#xD;
        ng/ml more than the PSA nadir in patient following radiotherapy, as defined by the&#xD;
        ASTRO-Phoenix criteria [18] and no evidence of malignancy on standard of care imaging for&#xD;
        metastases (CT of the chest/abdomen/pelvis and bone scan) within 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of a condition or abnormality that in the opinion of the Investigator would&#xD;
             compromise the safety of the patient or the quality of the data.&#xD;
&#xD;
          2. Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners&#xD;
             may not be able to function with patients over 450 pounds.&#xD;
&#xD;
          3. Change in therapy since standard of care imaging&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Fridman, PsyD, RN</last_name>
    <role>Study Director</role>
    <affiliation>Hoag Memorial Hospital Presbyterian</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Thomsen</last_name>
    <phone>949-764-4577</phone>
    <email>clinicalresearch@hoag.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Thomsen</last_name>
      <email>beth.thomsen@hoag.org</email>
    </contact>
    <investigator>
      <last_name>Gary Ulaner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hoag Memorial Hospital Presbyterian</investigator_affiliation>
    <investigator_full_name>Gary Ulaner</investigator_full_name>
    <investigator_title>Director Molecular Imaging and Therapy</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>DCFPyL PET/CT</keyword>
  <keyword>Staging</keyword>
  <keyword>Biochemical relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

